Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
SAN FRANCISCO - Hims & Hers Health, Inc., a prominent player in the health and wellness industry, has announced the acquisition of a US-based peptide manufacturing facility located in California. The move is aimed at bolstering the company’s domestic supply chain and enhancing its capability to consistently provide Americans with personalized medications.
The acquisition, which was finalized in early February, marks the latest step in the company’s strategy to vertically integrate its operations, ensuring a more reliable and efficient supply chain for its personalized healthcare products. This follows previous acquisitions of 503A and 503B facilities, underscoring Hims & Hers’ commitment to maintaining its operations within the United States, which allows for greater control over costs, availability, and quality.
Melissa Baird, COO of Hims & Hers, emphasized that the company’s operational structure is designed to scale personalized care to more individuals, maintaining the highest standards of quality and safety. "We’re building our supply chain to enable more Americans to access care, including personalized treatments designed around their needs," Baird said. "This acquisition is a reflection of our commitment to those goals and our ongoing investment in the customer from start to finish."
The new facility’s peptide capabilities are expected to position Hims & Hers to explore advances in peptide innovation in the coming years. Potential areas of development include preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances.
As personalized treatment demand continues to grow, Hims & Hers anticipates further strengthening of its infrastructure capabilities. This strategic acquisition is part of the company’s broader mission to normalize health and wellness challenges and provide easy-to-achieve solutions through personalized care.
This report is based on a press release statement from Hims & Hers Health, Inc.
In other recent news, Hims & Hers Health, Inc. has reported significant developments that are drawing attention from investors. The company experienced a notable 104% increase in online sales year-over-year for January, with GLP-1 drugs now making up about 40% of these sales, according to Bloomberg Second Measure data. Analysts from BofA Securities have updated their outlook, raising the price target to $21 while maintaining an Underperform rating, projecting first-quarter 2025 online revenue to range between $551 million and $574 million, surpassing consensus estimates. In a strategic move, Hims & Hers announced the acquisition of Trybe Labs, enhancing its platform with at-home lab testing capabilities to offer personalized healthcare options. This acquisition, funded with cash on hand, is expected to roll out over the next year, providing comprehensive testing services.
Furthermore, Canaccord Genuity raised its price target for Hims & Hers to $68, maintaining a Buy rating, reflecting optimism about the company’s growth prospects following a successful Super Bowl ad. BTIG also increased its price target to $85, citing positive performance in the direct-to-consumer health market and favorable market conditions. Both Canaccord and BTIG analysts express confidence in the company’s ability to capitalize on current trends and expand its healthcare offerings. These developments highlight Hims & Hers’ strategic efforts to enhance its market position and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.